[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-preeclampsia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-preeclampsia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,74,104,130,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644280","algorithm-based-timing-of-delivery-using-the-sflt-1plgf-ratio-in-early-onset-severe-preeclampsia-map-2-study--management-based-on-angiogenic-markers-in-preeclampsia-2-study--100644280",false,"NCT07665112","Algorithm-Based Timing of Delivery Using the sFlt-1\u002FPlGF Ratio in Early-Onset Severe Preeclampsia. (MAP 2 Study : Management Based on Angiogenic Markers in Preeclampsia 2 Study )","Multicenter Randomized Trial of an sFlt-1\u002FPlGF Ratio-Based Algorithm for Timing of Delivery in Early-Onset Severe Preeclampsia: The MAP 2 Study","MAP 2","Inclusion criteria :\n\n* Women aged 18 or older\n* Singleton pregnancies\n* Diagnosed with severe preeclampsia per 2020 ACOG criteria, between 30.0 and 33.6 weeks by first-trimester ultrasound.\n\nExclusion criteria :\n\n* Major fetal malformations\n* Confirmed genetic syndromes.","FEMALE","18 Years",{"count":20,"type":21},386,"ESTIMATED","INTERVENTIONAL",[24],"NA","Preeclampsia is a serious pregnancy complication caused by abnormal placental development and function. It can lead to high blood pressure and damage to organs such as the liver, kidneys, brain, or cardiovascular system. In these cases, the only definitive treatment is delivery. However, deciding when to deliver is challenging: delaying delivery increases risks for both mother and baby, while delivering too early increases complications related to prematurity.\n\nThis study aims to evaluate whether a blood test measuring the sFlt-1\u002FPlGF ratio an angiogenic marker that reflects placental function and predicts complications more accurately than traditional clinical criteria can help determine the optimal timing of delivery in women with severe preeclampsia between 30 weeks and 33 weeks plus 6 days of gestation. It is a multicenter, randomized controlled clinical trial conducted in 11 referral hospitals in Spain and will include 386 singleton pregnancies.\n\nParticipants will be randomly assigned to one of two groups. In the control group, standard expectant management will be followed, aiming to continue the pregnancy until 34 weeks if maternal and fetal conditions remain stable, and the sFlt-1\u002FPlGF results will be masked. In the study group, delivery timing will be guided by the sFlt-1\u002FPlGF ratio: if the ratio is greater than 655, delivery will be planned from 30 weeks onward; if greater than 110, delivery will be planned from 34 weeks; and if 110 or lower, pregnancy may continue until 37 weeks.\n\nThe study has two primary outcomes. The first is a composite of severe maternal complications, including neurological, hepatic, renal, respiratory, or cardiovascular dysfunction, severe hypertension, placental abruption, or fetal death. The second is a composite of neonatal complications, including admission to the neonatal intensive care unit or neonatal death.\n\nThe goal is to demonstrate that using angiogenic markers reduces maternal complications without significantly increasing neonatal complications. If successful, this approach could support more individualized management of early-onset severe preeclampsia, improving maternal safety while carefully balancing the risks of prematurity for the newborn.",[27],"Severe Preeclampsia",[29,30],"Angiogenic biomarkers","sFlt-1\u002FPlGF ratio","NOT_YET_RECRUITING","2026-06-18",{"date":34,"type":35},"2026-06-24","ACTUAL",{"date":37,"type":21},"2026-07-01",{"date":39,"type":21},"2029-12-31",{"name":41,"class":42},"Hospital Clinic of Barcelona","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100642539","phase-2-furosemide-vs-placebo-in-severe-preeclampsia-postpartum-100642539","NCT07648251","Furosemide vs Placebo in Severe Preeclampsia Postpartum","Furosemide Oral Versus Placebo for Reduction of Hospital Length of Stay in Postpartum Women With Severe Preeclampsia: A Double-Blind, Randomized Controlled Trial","FUROPE","Inclusion Criteria:\n\n* Signed informed consent (assent for minors 14-17 years with parental\u002Fguardian consent)\n* Confirmed severe preeclampsia (BP ≥160\u002F110 mmHg, or lower BP with thrombocytopenia, hepatic dysfunction, renal insufficiency, pulmonary edema, or cerebral\u002Fvisual symptoms)\n* Postpartum (12-24 hours after delivery, vaginal or cesarean)\n* Hemodynamically stable (no vasopressors for ≥6 hours)\n* Preserved diuresis (\\>30 mL\u002Fhour for ≥6 hours)\n* Serum creatinine \\\u003C0.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Current or chronic diuretic use (before or during pregnancy)\n* Known allergy to sulfonamides or furosemide\n* Active febrile illness\n* Known chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin\u002F1.73m²)\n* Participation in another interventional trial\n* Pregnancy (current - not applicable postpartum, but excludes undiagnosed concurrent pregnancy)","14 Years","49 Years",{"count":55,"type":21},186,[57],"PHASE2","This randomized, double-blind, placebo-controlled trial evaluates whether oral furosemide 40 mg, initiated 12 hours postpartum, reduces hospital length of stay compared to placebo (folic acid 5 mg) in postpartum women with severe preeclampsia. Secondary outcomes include need for rescue antihypertensive medications, weight reduction, and metabolic safety (hypokalemia, renal function). A total of 186 participants (93 per arm) will be enrolled across two hospitals in Honduras.",[27],[61,62,63,64,65],"Preeclampsia","Furosemide","Postpartum","Hypertension","Length of Stay","2026-06-09",{"date":68,"type":35},"2026-06-15",{"date":68,"type":21},{"date":71,"type":21},"2027-01-15",{"name":73,"class":42},"Universidad Nacional Autonoma de Honduras",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100635004","factors-associated-with-blood-pressure-control-failure-to-intravenous-labetalol-in-severe-preeclampsia-100635004","NCT07547046","Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe Preeclampsia","Assessment of the Association Between Predefined Factors and Response or Failure of Blood Pressure Control With Intravenous Labetalol Monotherapy in Severe Preeclampsia: a Multicenter Observational Study","RELAPSE","Inclusion Criteria:\n\n* Adult patient (age ≥ 18 years)\n* Pregnancy ≥ 24 weeks of gestation with one or more viable fetuses and severe preeclampsia requiring intravenous labetalol administration, either as continuous infusion (IVSE) or intravenous bolus titration\n\nExclusion Criteria:\n\n* Contraindication to labetalol (asthma, chronic obstructive pulmonary disease, bradycardia, current or history of intracardiac conduction disorders, or history of hypersensitivity reaction)\n* Intravenous antihypertensive treatment initiated prior to inclusion\n* Patient refusal or objection to the use of her healthcare data for research purposes",{"count":83,"type":21},350,"OBSERVATIONAL","Severe preeclampsia is a serious pregnancy complication that can lead to severe maternal and fetal outcomes, particularly when blood pressure is not adequately controlled. In France, intravenous labetalol is recommended as the first-line treatment for severe hypertension in preeclampsia. However, in clinical practice, failure to control blood pressure with labetalol is frequently observed, and the factors associated with this lack of response remain poorly understood.\n\nThe RELAPSE study is a prospective, multicenter observational study designed to identify factors associated with failure of blood pressure control with intravenous labetalol monotherapy in patients with severe preeclampsia.\n\nThe main hypothesis is that certain patient characteristics, such as maternal clinical profile, obstetric history, or biological parameters, may be associated with a higher risk of treatment failure. Identifying these factors could help clinicians better anticipate inadequate response to labetalol and adapt treatment strategies more rapidly.\n\nData will be collected from routine clinical care without modifying patient management. Patients will be followed from the initiation of intravenous labetalol until hospital discharge. The study will include approximately 350 patients across multiple centers.\n\nBy improving the understanding of predictors of treatment failure, this study aims to contribute to better management of severe preeclampsia and to reduce maternal and neonatal complications.",[27],[88,89,90,91,92,93],"Severe preeclampsia","hypertensive disorders of pregnancy","pregnancy-related hypertension","maternal morbidity","antihypertensive treatment fa","intravenous labetalol; blood pressure control","2026-04-20",{"date":96,"type":35},"2026-04-23",{"date":98,"type":21},"2026-04-01",{"date":100,"type":21},"2026-05-07",{"name":102,"class":42},"Assistance Publique - Hôpitaux de Paris",14,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":43},"100613342","excess-base-comparison-between-pregnant-subjects-with-severe-preeclampsia-vs-normotensive-pregnant-women-100613342","NCT07265336","Excess Base Comparison Between Pregnant Subjects With Severe Preeclampsia vs. Normotensive Pregnant Women","Comparison of Base Excess in Arterial Blood Gases Between Patients With Severe Preeclampsia and Normotensive Pregnant Patients","Inclusion Criteria:\n\n* Gestational age: 24-40 weeks\n* Cases: Diagnosis of severe preeclampsia\n* Control: Normal blood pressure\n\nExclusion Criteria:\n\n* Metabolic conditions that could hinder the results (diabetic ketoacidosis, sepsis, renal failure).\n* Clinical conditions that could hinder the results (diarrhea, vomit)\n* Recent use of bicarbonate",true,{"count":113,"type":21},100,[24],"The study's primary goal is to compare the base excess (BE) values-an indicator of metabolic changes-in two groups of patients at Santo Tomás Hospital: those with severe preeclampsia and healthy, pregnant individuals. Researchers will measure these values using an arterial blood gas test before delivery or surgery.\n\nThis is a prospective cohort study. The researchers will analyze various blood gas parameters, including pH, lactate, and BE, and then correlate the BE values with clinical variables and negative maternal outcomes.\n\nThe expected outcome is that a abnormal BE values will be linked to a greater severity of preeclampsia. If this association is confirmed, BE could serve as an additional marker for predicting the severity of the condition and may lay the groundwork for future research on diagnostic and therapeutic standards based on blood gas analysis.",[61,27],[118,88,119],"Excess base","Arterial blood gases","RECRUITING","2025-12-02",{"date":123,"type":35},"2025-12-04",{"date":125,"type":35},"2025-08-15",{"date":127,"type":21},"2026-01-31",{"name":129,"class":42},"Saint Thomas Hospital, Panama",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":43},"100609924","phase-3-levetiracetam-compared-to-magnesium-sulfate-for-prevention-of-eclamptic-seizure-100609924","NCT07220902","Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure","Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure: A Randomized Controlled Trial \"LEVMag Trial\"","LEVMag","Inclusion Criteria:\n\n* Pregnant or postpartum women aged 19 years or older\n* Diagnosed with preeclampsia with severe features, superimposed preeclampsia or HELLP syndrome\n* At risk for eclampsia and eligible for seizure prophylaxis\n* Less than 2 hours exposure to magnesium sulfate or greater than 48 hours since last dose.\n* Admitted or plan to proceed with delivery\n\nExclusion Criteria:\n\n* \\\u003C32 weeks estimated gestational age\n* History of epilepsy or seizure disorders unrelated to pregnancy\n* Allergy or contraindication to Levetiracetam or Magnesium Sulfate\n* Severe renal impairment (Oliguria \\\u003C120ml in 4 hours)\n* Plan for neonatal comfort care","19 Years",{"count":140,"type":21},1240,[142],"PHASE3","The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This is an equivalence study so our primary goal is to see no difference in the incidence of seizure in the two groups. Since side effects can be a significant problem with magnesium sulfate and these patients are at significant risk of life threatening complications, we also plan to evaluate several secondary outcomes in the mothers and the babies, including:\n\nsevere allergic reaction, magnesium toxicity, ICU admission, hospital readmission, transfusion for any reason, pulmonary edema, cardiomyopathy, Posterior Reversible Encephalopathy Syndrome, eclamptic seizure, loss of vision, stroke, renal injury requiring dialysis, cardiac arrest, maternal death, unexpected stillbirth or neonatal death, NICU admission, Apgars and length of neonatal respiratory support.",[27,145],"Eclampsia Preeclampsia",[147,148,61,149,150,151,152,136,153],"Seizure","Prophylaxis","Eclampsia","Keppra","Levetiracetam","Magnesium","Equivalence","2025-10-22",{"date":156,"type":35},"2025-10-24",{"date":158,"type":21},"2026-01-01",{"date":160,"type":21},"2034-07",{"name":162,"class":42},"Nebraska Methodist Health System",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":4},"100553433","phase-1-protocols-for-magnesium-sulfate-maintenance-dose-in-overweight-and-obese-women-diagnosed-with-preeclampsia-100553433","NCT06486025","Protocols for Magnesium Sulfate Maintenance Dose in Overweight and Obese Women Diagnosed With Preeclampsia","ALTERNATE DOSING PROTOCOL FOR MAGNESIUM SULFATE IN OVERWEIGHT AND OBESE WOMEN WITH PREECLAMPISA: A RANDOMIZED CONTROLLED TRIAL","Inclusion Criteria:\n\nWomen diagnosed with SPET as per criteria of NICE, 2023 guidance\n\n* Age 20-40 years\n* BMI \\>25kg\u002Fm2\n* Gestational age \\> 28 weeks\n\nExclusion Criteria:\n\n* Intrauterine Fetal Death (IUFD)\n* Hemolysis - Elevated liver enzymes - Low platelets syndrome (HELLP)\n* Contraindication to Magnesium Sulfate such as myasthenia gravis, severe renal failure, cardiac ischemia, and heart block\n* Serum creatinine levels greater than 1.1 mg\u002FdL.\n* Women refusing to participate in the study.","20 Years","40 Years",{"count":113,"type":21},[174,57],"PHASE1","There is still no evidence of the appropriate dose to be used. Serum magnesium sulfate concentration is not measured regularly, thus we may be using sub-therapeutic level or reaching a toxic level.Overweight and obese women have different pharmacokinetics and different drug distribution, therefore, they may need higher doses of magnesium sulfate to reach therapeutic level.",[27],"2024-06-27",{"date":179,"type":35},"2024-07-03",{"date":181,"type":21},"2024-07-01",{"date":183,"type":21},"2024-10-01",{"name":185,"class":42},"Ain Shams University"]